Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Xian Risperdal vs Gurabo Risperdal in Healthy Chinese Subjects
NCT03220867Phase 1Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of risperidone in schizophrenia (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration at 96 hours, Area Under Concentration-Time Curve From Time Zero to the Last Quantifiable at 96 hours and 1 more. Planned start Dec 2017; status: withdrawn.
02
Drugs
risperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03220867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03220867.